Last reviewed · How we verify

Angiotensin II Receptor Blockers

Ottawa Heart Institute Research Corporation · Phase 3 active Small molecule

Angiotensin II Receptor Blockers is a Angiotensin II Receptor Blocker (ARB) Small molecule drug developed by Ottawa Heart Institute Research Corporation. It is currently in Phase 3 development for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction cardioprotection. Also known as: azilsartan, candesartan, eprosartan, Irbesartan.

Angiotensin II Receptor Blockers (ARBs) block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure.

Angiotensin II Receptor Blockers (ARBs) block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction cardioprotection.

At a glance

Generic nameAngiotensin II Receptor Blockers
Also known asazilsartan, candesartan, eprosartan, Irbesartan, losartan
SponsorOttawa Heart Institute Research Corporation
Drug classAngiotensin II Receptor Blocker (ARB)
TargetAT1 receptor (Angiotensin II Type 1 Receptor)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

ARBs selectively antagonize AT1 receptors on vascular smooth muscle and adrenal tissue, inhibiting the renin-angiotensin-aldosterone system (RAAS). This prevents angiotensin II-mediated vasoconstriction, sodium retention, and sympathetic activation, resulting in vasodilation and reduced blood pressure. ARBs are commonly used for hypertension management and have cardioprotective effects in heart failure and post-myocardial infarction patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Angiotensin II Receptor Blockers

What is Angiotensin II Receptor Blockers?

Angiotensin II Receptor Blockers is a Angiotensin II Receptor Blocker (ARB) drug developed by Ottawa Heart Institute Research Corporation, indicated for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction cardioprotection.

How does Angiotensin II Receptor Blockers work?

Angiotensin II Receptor Blockers (ARBs) block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure.

What is Angiotensin II Receptor Blockers used for?

Angiotensin II Receptor Blockers is indicated for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction cardioprotection, Diabetic nephropathy.

Who makes Angiotensin II Receptor Blockers?

Angiotensin II Receptor Blockers is developed by Ottawa Heart Institute Research Corporation (see full Ottawa Heart Institute Research Corporation pipeline at /company/ottawa-heart-institute-research-corporation).

Is Angiotensin II Receptor Blockers also known as anything else?

Angiotensin II Receptor Blockers is also known as azilsartan, candesartan, eprosartan, Irbesartan, losartan.

What drug class is Angiotensin II Receptor Blockers in?

Angiotensin II Receptor Blockers belongs to the Angiotensin II Receptor Blocker (ARB) class. See all Angiotensin II Receptor Blocker (ARB) drugs at /class/angiotensin-ii-receptor-blocker-arb.

What development phase is Angiotensin II Receptor Blockers in?

Angiotensin II Receptor Blockers is in Phase 3.

What are the side effects of Angiotensin II Receptor Blockers?

Common side effects of Angiotensin II Receptor Blockers include Hyperkalemia, Dizziness, Fatigue, Hypotension, Cough (less common than with ACE inhibitors).

What does Angiotensin II Receptor Blockers target?

Angiotensin II Receptor Blockers targets AT1 receptor (Angiotensin II Type 1 Receptor) and is a Angiotensin II Receptor Blocker (ARB).

Related